Opinion

Video

Shared Decision-making for Selection of FDA-approved Therapies for NMOSD

Key Takeaways

  • Efficacy, safety, dosing frequency, and patient-specific factors are key in selecting NMOSD therapies.
  • Eculizumab and ravulizumab may be preferred for patients with severe relapses or contraindications to B-cell depletion.
SHOW MORE

A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab. Shared decision-making is crucial, involving close collaboration between the healthcare team and the patient to develop a personalized treatment plan that considers the patient's overall well-being.

Video content above is prompted by the following:

  • What factors should be considered when choosing between other available FDA-approved therapies (eculizumab, inebilizumab, satralizumab, and ravulizumab) for patients with NMOSD?
  • What clinical characteristics can help guide neurologists in selecting eculizumab or ravulizumab versus rituximab?
  • Discuss shared decision-making when managing patients with APQ4+ NMOSD.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Videos
Anna Pace, MD
Kristyn Pocock, MD
Dementia expert James Galvin, MD, MPH, a professor of neurology at the University of Miami Miller School of Medicine, and chief scientific officer at CogniVue
Rami Burstein, PhD
Michael Kaplitt, MD, PhD
2 experts are featured in this series.
2 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.